Skip Navigation

Nephrology Dialysis Transplantation 2006 21(6):1461-1464; doi:10.1093/ndt/gfi317
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McClellan, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McClellan, W. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

The epidemic of renal disease—what drives it and what can be done?

William M. McClellan1,2

1 Department of Internal Medicine, Section of Nephrology and 2 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

Correspondence and offprint requests to: William M. McClellan, Email: bmcclell{at}gmcf.org

Keywords: epidemiologic transition; ESRD; primary prevention; secondary prevention

Contemporary societies are in the midst of an epidemic of end-stage renal disease (ESRD). The epidemic is partially a consequence of profound gains in life span that occurred in economically developed world regions beginning in the 19th century, where life expectancy at birth increased during the 20th century on average at 2–3 months per year [1]. This remarkable achievement has been termed the epidemiologic transition and is partially attributable to a stage of better nutrition and a second stage characterized by control of infection [2]. A welcome consequence of these two stages of the epidemiologic transition has been improved survival during childhood and young adulthood as is illustrated by China (Figure 1), where the traditional pyramid has been transformed to a ‘population box’ [3,4].


Figure 1
View larger version (40K):
[in this window]
[in a new window]
  		Fig. 1. Estimated year 2000 and projected year 2025 population structures for China demonstrating the impact of the epidemiologic transition on the proportion of older individuals subject to chronic disease.

 
An unwanted consequence of this extension of life has been the emergence of chronic diseases in ageing societies as leading causes of death during the 20th century, a shift that has been termed the third stage of the epidemiologic transition. The emergence of ESRD as a world health burden [5,6] is an example of this transition [7]. The thesis posed here is that responding to this epidemic of ESRD should emphasize improved delivery of existing renal replacement and reno-protective therapies in economically less developed world regions.

The ESRD epidemic has recently been thoroughly discussed in symposia where a major focus has been on strategies to increase the detection, treatment and control of early kidney disease (secondary prevention) in developing world regions [8–11]. While this emphasis is important and necessary, it should not obscure the likely growth of ESRD and the need for renal replacement therapy in these regions, because these regions are just beginning to experience the shift to chronic disease and ageing populations that are conducive to exponential growth in ESRD. This is illustrated by the Global Burden of Disease Study (GBDS) [12]. The GBDS grouped major causes of death in eight world regions, defined by level of socioeconomic development, epidemiologic homogeneity, and geography, into three groups: one characteristic of the first stages of the epidemiologic transition and consisting of infectious diseases, maternal and perinatal causes and nutritional deficiencies; the second, characterized by chronic diseases found in modern societies; and the third, characterized by deaths due to intentional or unintentional injuries common to all stages of the epidemiologic transition. The variability of the transition is evident in Figure 2 where, in contrast to developed world regions, deaths due to chronic diseases in sub-Saharan Africa account for only 20% of the burden of mortality.


Figure 2
View larger version (32K):
[in this window]
[in a new window]
  		Fig. 2. Estimated proportion of deaths attributable to chronic disease by world region, from the Global Burden of Disease study, illustrates the variability in the third stage of the epidemiologic transition. Adapted from Table 2, Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–76. EME = established market economies; FSE = formerly socialist economies of Europe; IND = India; CHN = China; OAI = other Asia and islands; SSA = sub-Saharan Africa; LAC = Latin America and the Caribbean; MEC = middle eastern crescent.

 
Effective secondary prevention strategies may not fully attenuate the short-term growth of ESRD during the epidemiologic transition. This is illustrated by the United States (US) experience where, as the population made its transition from high mortality, young populations and shorter life expectancy to low mortality, longer life and chronic disease, ESRD incidence rose through the middle and late 20th century. Recently, the year-to-year increase in ESRD incidence has slowed to less than 1% in 2000 and 2001 and it appears that the peak of the epidemic may soon be observed in virtually all age, race and disease groups [13]. Despite this substantial reduction in incident rates, the ESRD burden will continue to grow in the USA, due to continuing changes in demographic structure and diabetes prevalence [14]. After accounting for these factors and the reduction in ESRD incidence, it is predicted that incidence and prevalence of ESRD in the USA will increase by 32 and 70%, respectively by 2015 [14].

This means that, while primary and secondary prevention programmes will ultimately reduce the burden of ESRD throughout the world, there may be a ‘built in’ growth in ESRD numbers in developing countries. Some provision for providing renal replacement therapy (RRT) for these patients in less well-developed world regions on the escalator to ESRD needs to be considered. Developing regions will be stretched, at best, to afford this care as it is currently organized and delivered. While new technologies might someday be less expensive, it is more likely that we will need to find less expensive and more efficient ways of using our existing dialysis technologies. This is a major challenge which will call for new social and administrative policies and infrastructure models. While it is not apparent where these ideas will come from, perhaps a proposal for Australia and New Zealand to shift dialysis treatment to home and self-care models is an example of this type of innovation [15].

What about primary prevention of progressive kidney disease? It is necessary to recognize that increasing rates of ESRD are a consequence of the improved material circumstances and increased longevity of modern life. Thus, primary prevention of ESRD, as with other chronic diseases, must be based on interventions that adapt health systems and modify health related behaviours to these conditions. Frequently discussed in this context are nutrition policies. For example, the worldwide increase in ESRD incidence partially reflects increased obesity-related hypertension and diabetes in sedentary, well-nourished populations [16–19]. In the US, increased prevalence of diabetes, myocardial infarction (MI) and stroke survivors account for nearly a third of the recent increase in ESRD (diabetes, 27.6%; increased MI and stroke survival, 4.8%), while population growth accounts for less than 10% of the increase [20]. National nutrition policies seeking to influence the burden of ESRD might be targeted at obesity through strategies to moderate diets and increase daily energy expenditures. It is equally important to note that at present, the evidence upon which any policy and primary prevention strategy for kidney disease can be based is sparse to non-existent. Thus, if population-based prevention programmes are to impact on the epidemic of ESRD, it is imperative that research on these issues be initiated and supported [21].

A final consideration for dealing with the immediate consequences of this epidemic of ESRD is the importance of our existing therapies for secondary prevention of progressive kidney disease. Declines in cardiovascular disease and stroke [22,23] during the last century, and cancer [23,24] in Europe and the USA during this century demonstrate that chronic diseases can be controlled. The epidemic of coronary heart disease peaked early in the era of modern cardiovascular therapeutics (Figure 3) and both primary prevention and medical care contributed about equally to the overall decline [25,26]. Much of the decline in cardiovascular diseases occurred before contemporary therapies like HMG-CoA reductase inhibitors (statins) which were only available after 1987 [27].


Figure 3
View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3. The epidemic of cardiovascular disease in the United States began to decline following development of first generation prevention therapies. Morbidity and mortality weekly report 1999: 48: 649–656.

 
It is reasonable to suggest that the first generation of effective therapies for progressive kidney disease may have had a similar impact on the ESRD incidence. Certainly the declining ESRD incidence rates in the USA [13] and continuing reports of regional declines in type 1 diabetic nephropathy incidence rates [28,29] are consistent with this possibility. The recent advent of effective reno-protective therapy means that secondary prevention programmes based on the early detection of kidney disease must also provide access to these existing therapies [8–11]. This is widely recognized as a problem for economically developing regions similar to that of providing RRT. Another challenge will be to develop health care models and therapies that extend existing renoprotective care to patients in economically developing regions of the world. The programme described by Hoy et al. for Australian aborigines is a pragmatic, local example of the type of innovative health care model needed for these populations that effectively delivers existing renoprotective therapy [30].

In summary, the worldwide epidemic of ESRD is an unwanted consequence of the improved material circumstances and longevity of modern life. As these desired circumstances spread from the economically developed to the developing world, it can be expected that increasing numbers of people will require RRT and that existing technologies will be required to meet the ensuing demand. Secondary prevention programmes may attenuate some of this growth in worldwide ESRD if we can deliver existing reno-protective therapies to individuals in these economically developing regions. Finally, population-based primary prevention of kidney disease will ultimately reduce the long-term growth in ESRD if we can identify effective intervention strategies. Thus, it is reasonable to suggest that, for the near future, adaptation and translation of existing therapies to populations now entering the third stage of the epidemiologic transition, with its ‘built in growth’ of ESRD, will be a major public health and medical challenge.

Conflict of interest statement. None declared.



   References
Top
 References
 

  1. Oeppen J, Vaupel JW. Demography: enhanced: broken limits to life expectancy. Science 2002; 296: 1029–1031[Abstract/Free Full Text]
  2. Omran AR. The epidemiological transition: a theory of epidemiology of population change. Milbank Mem Fund Q 1971; 49: 509–538[CrossRef][Web of Science][Medline]
  3. Notestein FW. Demographic studies of selected areas of rapid growth. In: Proceedings of the round table on population problems, 22nd annual conference of the Milbank Memorial Fund. New York: Milbank Memorial Fund; 1945
  4. Vaupel JW, Carey JR, Christensen K et al. Biodemographic trajectories of longevity. Science 1998; 280: 855–860[Abstract/Free Full Text]
  5. Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. Am J Kidney Dis 2005; 45: 201–208[Medline]
  6. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005; 15: 418–423[Web of Science][Medline]
  7. Correa-Rotter R, Naicker S, Katz IJ et al. Demographic and epidemiologic transition in the developing world: role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease. Kidney Int Suppl 2004; 92: S32–S37[Medline]
  8. Ramirez SP. Summit on kidney disease prevention participants. First international summit on kidney disease prevention, 25–27 July 2002: consensus document. J Am Soc Nephrol 2003; 14 [7 Suppl 2]: S205–S207[CrossRef]
  9. Li PK, Weening JJ, Dirks J et al. Participants of ISN Consensus Workshop on Prevention of Progression of Renal Disease: a report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl 2005; 67 [Suppl 94]: S2–S7
  10. Agodoa L, Norris K, Pugsley DJ. Proceeding of the Ensenada (Mexico) conference on renal disease in minority groups, with emphasis on the Americas. Kidney Int Suppl 2005; 68 [Suppl 97]: S1–S3
  11. Dirks JH, de Zeeuw D, Agarwal SK et al. Prevention of chronic kidney and vascular disease: toward global health equity–the Bellagio 2004 Declaration. Kidney Int Suppl 2005; 68 [Suppl 98]: S1–S6
  12. Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 1996; 274: 740–743[Free Full Text]
  13. U.S. Renal Data System, USRDS 2005 Annual data report: atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
  14. Gilbertson D, Liu J, Xue J et al. Projecting the number of end-stage renal disease patients in the United States to the Year 2015. J Am Soc Nephrol 2005: 3736–3741
  15. Lynn KL, Buttimore AL. Future of home haemodialysis in Australia and New Zealand. Nephrology (Carlton). 2005; 10: 231–233[Medline]
  16. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 1723–1727.[Abstract/Free Full Text]
  17. World Health Organization (2000) Obesity: preventing and managing the global epidemic WHO Obesity Technical Report Series 894 World Health Organization Geneva, Switzerland
  18. Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled ‘hypertensive nephrosclerosis’. J Hypertens 2004; 22: 1051–1055.[CrossRef][Web of Science][Medline]
  19. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479–487[Web of Science][Medline]
  20. Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003; 14: 1568–1577[Abstract/Free Full Text]
  21. Centers for disease control and prevention (CDC): Barriers to children walking to or from school – United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54: 949–952.[Medline]
  22. Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000; 355: 688–700.[CrossRef][Web of Science][Medline]
  23. Thom TJ, Epstein FH. Heart disease, cancer, and stroke mortality trends and their interrelations: an international perspective. Circulation 1994; 90: 574–582.[Abstract/Free Full Text]
  24. Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer 2004; 40: 96–125[CrossRef][Web of Science][Medline]
  25. Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004; 117: 219–227.[CrossRef][Web of Science][Medline]
  26. Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000; 355: 688–700.[CrossRef][Web of Science][Medline]
  27. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2: 517–526[CrossRef][Web of Science][Medline]
  28. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15–18.[Abstract/Free Full Text]
  29. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Linkoping diabetes complications study: declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes-the Linkoping diabetes complications study. Diabetologia 2004; 47: 1266–1272.[Web of Science][Medline]
  30. Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J, Sharma S, Katz I. A chronic disease outreach program for aboriginal communities. Kidney Int Suppl 2005; 68 [Suppl 98]: S76–S82
Received for publication: 2.11.05
Accepted in revised form: 14.11.05


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
H. Bang, M. Mazumdar, G. Newman, A. S. Bomback, C. M. Ballantyne, A. S. Jaffe, P. A. August, and A. V. Kshirsagar
Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience
Nephrol. Dial. Transplant., March 26, 2009; (2009) gfp124v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. E. Vikse, L. M. Irgens, T. Leivestad, S. Hallan, and B. M. Iversen
Low Birth Weight Increases Risk for End-Stage Renal Disease
J. Am. Soc. Nephrol., January 1, 2008; 19(1): 151 - 157.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McClellan, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McClellan, W. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?